RETEVMO (selpercatinib), FDA-Approved for Treatment of RET-driven Lung and Thyroid Cancers, Available at Biologics by McKesson
CARY, N.C., June 2 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Eli Lilly and Company as a specialty pharmacy provider for RETEVMOTM (selpercatinib), the first drug approved by the U.S. Food and Drug Administration (FD...
Source: McKesson News - Category: Information Technology Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Information Technology | Rare Diseases | Thyroid | Thyroid Cancer